JPH02255621A - Hypotensor - Google Patents
HypotensorInfo
- Publication number
- JPH02255621A JPH02255621A JP1075196A JP7519689A JPH02255621A JP H02255621 A JPH02255621 A JP H02255621A JP 1075196 A JP1075196 A JP 1075196A JP 7519689 A JP7519689 A JP 7519689A JP H02255621 A JPH02255621 A JP H02255621A
- Authority
- JP
- Japan
- Prior art keywords
- pts
- root
- rhizome
- weight
- senkyu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002220 antihypertensive agent Substances 0.000 claims description 12
- 229940030600 antihypertensive agent Drugs 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 20
- 239000000843 powder Substances 0.000 abstract description 18
- 239000007788 liquid Substances 0.000 abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 7
- 244000018633 Prunus armeniaca Species 0.000 abstract description 7
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 235000008434 ginseng Nutrition 0.000 abstract description 4
- 229910052602 gypsum Inorganic materials 0.000 abstract description 4
- 239000010440 gypsum Substances 0.000 abstract description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 239000003390 Chinese drug Substances 0.000 abstract 3
- 240000004371 Panax ginseng Species 0.000 abstract 3
- 235000002789 Panax ginseng Nutrition 0.000 abstract 3
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 2
- 241001465251 Ephedra sinica Species 0.000 abstract 2
- 244000273928 Zingiber officinale Species 0.000 abstract 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 2
- 235000008397 ginger Nutrition 0.000 abstract 2
- 239000004575 stone Substances 0.000 abstract 2
- 239000001841 zingiber officinale Substances 0.000 abstract 2
- 241001671653 Aconitum carmichaelii Species 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 235000011446 Amygdalus persica Nutrition 0.000 abstract 1
- 241000544270 Angelica acutiloba Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 abstract 1
- 241000208809 Carthamus Species 0.000 abstract 1
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000237636 Pheretima Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241001369613 Stephania tetrandra Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000008609 bushi Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000010330 ougon Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 108010021724 tonin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 12
- 241000411851 herbal medicine Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000218671 Ephedra Species 0.000 description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940010454 licorice Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 244000000626 Daucus carota Species 0.000 description 3
- 235000002767 Daucus carota Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000010396 fuzi Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101150055297 SET1 gene Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、高血圧疾患の治療に有効な薬剤に関するもの
である。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a drug effective in treating hypertensive diseases.
［従来の技術および課題］
高血圧状態が長期間持続することにより、脳、心臓、腎
臓等の重要な臓器に重大な合併症を起こすことが知られ
ており、適切な降圧治療を行うことか必要である。降圧
治療に使用される降圧剤は種々有るが、急に血圧を下げ
ると低カリウム血症、全身倦怠、食欲不振、背部不快感
等の副作用が懸念される。そこで副作用の少ない、しか
も穏やかな降圧剤が望まれていた。[Prior art and issues] It is known that prolonged hypertension can cause serious complications in important organs such as the brain, heart, and kidneys, and it is necessary to provide appropriate antihypertensive treatment. It is. There are various antihypertensive drugs used for antihypertensive treatment, but there are concerns that sudden lowering of blood pressure may cause side effects such as hypokalemia, general malaise, loss of appetite, and back discomfort. Therefore, a gentle antihypertensive agent with fewer side effects was desired.
［課題を解決するための手段］
本発明者等は種々の漢方処方について、降圧作用に関す
る研究を行った結果、補陽還五湯、続命湯、小続命湯に
降圧作用の有ることを見い出し本発明を完成した。すな
わち本発明は補陽還五渇、続命湯および小続命湯から選
ばれる少なくともひとつの漢方処方を有効成分とする降
圧剤である。[Means for Solving the Problems] As a result of research into the antihypertensive effects of various Chinese herbal prescriptions, the present inventors found that Hoyokangoto, Zokumeito, and Shozokumeito have antihypertensive effects. Heading Completing the Invention. That is, the present invention is an antihypertensive agent containing at least one Chinese herbal formula selected from Hoyokangoto, Shoseimeito, and Shosetsumeito as an active ingredient.
補陽還五湯、統命湯および小統命場はそれぞれ漢方処方
の古典である医林改錯、金圓要路および備急千金要方に
その構成生薬、分量、抽出法等が記載されているか、降
圧作用を有することは従来全く知られていなかった。Hoyokangoto, Tomeito, and Shotomeiba are listed in the classic Chinese herbal medicine prescriptions Irin Kaihan, Kinen Yoro, and Bikyu Senkin Yokata, respectively, with their constituent herbal medicines, amounts, extraction methods, etc. However, it was not previously known that it had any antihypertensive effect.
本発明でいうところの補陽還五湯、続命湯、小続命湯と
は、それぞれ医林改錯、金属要路、備急千金要方等の古
典の記載に則った生薬の配合割合により生産される補陽
還五湯、続命湯、小続命湯であれば、いかなるものでも
構わない。In the present invention, Hoyokangoto, Zokumeito, and Kozukumeito are the proportions of herbal medicines that are in accordance with the descriptions of classics such as Iryin Kaikan, Metal Koro, and Bikyu Senkin Yokata, respectively. Any Hoyokangoto, Shokumeito, or Kotsumeito produced by the above may be used.
補陽還五場の各生薬の配合割合を例示するならば黄１５
重量部、桃仁２重量部、当帰３重量部、勺薬３重量部、
紅花２重量部、川ぢ２重量部、地竜２重量部が好ましい
。An example of the proportion of each herbal medicine in Hoyokan Goba is Yellow 15.
parts by weight, Momohin 2 parts by weight, Dangki 3 parts by weight, Chinese medicine 3 parts by weight,
Preferably, 2 parts by weight of Safflower, 2 parts by weight of Kawaji, and 2 parts by weight of Jiryu.
補陽還五湯は、例えば、買置５ｇ、桃仁２ｇ、当帰３９
．５薬３ｇ、紅花２ｇ、川荀２ｇ、地竜２ｇを６００７
の水で煎じて３００１１１とし、滓を取り去った薬液を
降圧剤として３回に分けて服用することもできるが、服
用のし易さ、携帯の便利さを考慮して乾燥エキス粉末と
したもの、またはこれを製剤化して漢方薬エキス製剤と
したものを降圧剤として用いることもできる。For example, Hoyokangoto is 5g of buying, 2g of momojin, and 39g of toki.
．． 5 medicine 3g, Safflower 2g, Chuanxun 2g, Earth Dragon 2g 6007
300111 is prepared by decoction with water and the dregs are removed, and the medicinal solution can be taken in three doses as an antihypertensive agent, but in order to make it easier to take and carry, it has been made into a dry extract powder. Alternatively, it can also be formulated into a Chinese herbal medicine extract preparation and used as an antihypertensive agent.
特に下記の方法のもとに製造される補陽還五湯がその薬
理作用を期待する上で好ましい。In particular, Hoyokangoto, which is produced according to the method described below, is preferred in view of its expected pharmacological effects.
補陽還五湯の製造の具体例を示すと以下の通りである。A specific example of the production of Hoyokangoto is as follows.
具体例１
漢方の古典（医林錯改）に則って、買置５９、桃仁２９
、当帰３ｇ、勺薬３９、紅花２ｇ、側角２９、地竜２ｇ
に３２倍量の精製水を加え、１００℃で６０分間程度抽
出し、固液分離し、得られた分離液が２分の１量になる
まで濃縮し、濃縮液をスプレードライして補陽還五堝乾
燥エキス粉末を得た。Specific example 1: In accordance with the classic Chinese medicine (Irin Kankai), 59 buys and 29 Momohin
, Toki 3g, Akuyaku 39, Safflower 2g, Side Horn 29, Earth Dragon 2g
Add 32 times the volume of purified water, extract at 100℃ for about 60 minutes, separate solid and liquid, concentrate the resulting separated liquid to 1/2 the volume, spray dry the concentrated liquid and make a Kangobo dry extract powder was obtained.
続命湯の各生薬の割合を例示するならば杏仁４重量部、
麻黄３重量部、桂枝３重量部、人参３重量部、当帰３重
量部、川角２重量部、乾美。Examples of the proportions of each herbal medicine in Shōmeito include 4 parts by weight of apricot kernels;
Ephedra 3 parts by weight, Keishi 3 parts by weight, ginseng 3 parts by weight, Toki 3 parts by weight, Kawakaku 2 parts by weight, Inuibi.
２重量部、甘草２重量部、石膏６重量部が好ましい。2 parts by weight, 2 parts by weight of licorice, and 6 parts by weight of gypsum.
続命湯は、例えば、杏仁４ｇ、麻黄３９、桂枝３９、人
参３９、当帰３９、川荀２９、乾美２ｇ、甘草２９、石
膏６ｇを６００−の水で煎じて３００ＩＩｉとし、滓を
取り去った薬液を降圧剤として３回に分けて服用するこ
ともできるが、服用のし易さ、携帯の便利さを考慮して
乾燥エキス粉末としたもの、またはこれを製剤化して漢
方薬エキス製剤としたものを降圧剤として用いることも
できる。For example, Shumeito is made by boiling 4 g of apricot kernels, 39 ephedra, 39 g of Katsura, 39 of ginseng, 39 of Toki, 29 of Kawano, 2 g of Inui, 29 of licorice, and 6 g of gypsum to make 300 IIi in 600-g water, and the dregs. The removed medicinal solution can be taken in three doses as an antihypertensive agent, but for ease of administration and portability, it can be made into a dry extract powder or formulated into a Chinese herbal medicine extract preparation. It can also be used as an antihypertensive agent.
特に下記の方法のもとに製造される続命湯がその薬理作
用を期待する上で好ましい。In particular, Seimeito produced by the method described below is preferred in view of its expected pharmacological effects.
続命湯の製造の具体例を示すと以下の通りである。A specific example of the production of Shomeito is as follows.
具体例２
漢方の古典（金圓要路）に則つて、杏仁４９、麻黄３９
、桂枝３ｇ、人参３ｇ、当帰３２、側角２ｇ、乾美２ｇ
、甘草２ｇ、石膏６ｇに２２倍量の精製水を加え、１０
０℃で６０分間程度抽出し、固液分離し、得られた分離
液が２分の１ｆｆｉになるまで濃縮し、濃縮液をスプレ
ードライして続命湯乾燥エキス粉末を得た。Specific example 2: According to the classic Chinese medicine (Kinyuan Yoro), 49% of apricot kernels and 39% of ephedra
, Katsuragi 3g, Carrot 3g, Toki 32, Side Horn 2g, Inui 2g
, add 22 times the amount of purified water to 2 g of licorice, 6 g of gypsum, and make 10
Extraction was carried out at 0° C. for about 60 minutes, followed by solid-liquid separation, and the resulting separated liquid was concentrated to 1/2 ffi, and the concentrated liquid was spray-dried to obtain a powder of Shumeito dry extract.
小統命湯の各生薬の配合割合を例示するならば杏仁３重
量部、防風２重量部、勺薬２重量部、防已２重量部、麻
黄２重量部、川角２重量部、黄苓２重量部、桂皮２重量
部、甘草１重量部、人参１重量部、生薬１重量部、附子
０．３重量部か好ましい。Examples of the proportions of each herbal medicine in Kotomeito are: 3 parts by weight of apricot, 2 parts by weight of Bofu, 2 parts by weight of Ephedra, 2 parts by weight of Boho, 2 parts by weight of Ephedra, 2 parts by weight of Kawakaku, and 2 parts by weight of Huangrei. Parts by weight, 2 parts by weight of cinnamon, 1 part by weight of licorice, 1 part by weight of ginseng, 1 part by weight of crude drugs, and 0.3 parts by weight of Fuzi are preferred.
小続命湯は、例えば、杏仁３９、防風２９、勺薬２９、
防已２９、麻黄２９、側角２ｇ、黄苓２９、桂皮２ｇ、
甘草ｔｇ、人参１ｇ、生薬１１、附子０．３９を６００
１１１の水で煎じて３００１！１ｆｔとし、滓を取り去
った薬液を降圧剤として３回に分けて服用することもで
きるが、服用のし易さ、携帯の便利さを考慮して乾燥エ
キス粉末としたもの、またはこれを製剤化して漢方薬エ
キス製剤としたものを降圧剤として用いることもできる
。For example, Kotsumeito is 39% of apricot, 29% of windproof, 29% of yakuyaku,
Boi 29, ephedra 29, side horn 2g, Huangrei 29, cinnamon bark 2g,
Licorice TG, carrot 1g, herbal medicine 11, Fuzi 0.39 for 600
111 in water to make 3001!1 ft. After removing the dregs, the medicinal solution can be taken in three doses as an antihypertensive agent, but in order to make it easier to take and carry, we have prepared a dry extract powder. It can also be used as an antihypertensive agent, or it can be formulated into a Chinese herbal medicine extract preparation.
特に下記の方法のもとに製造される小続命湯がその薬理
作用を期待する上で好ましい。In particular, Kozumeito produced by the method described below is preferred in view of its expected pharmacological effects.
小続命湯の製造の具体例を示すと以下の通りである。A specific example of the production of Kozumeito is as follows.
具体例３
漢方の古典（備急千金要方）に則って、杏仁３ｇ、防風
２ｇ、勺薬２ｇ、防已２ｇ、麻黄２９、黄苓２９、側角
２ｇ、黄苓２ｇ、桂皮２ｇ、甘草１９、人参１９、生薬
１９、附子０．３９に３０倍量の精製水を加え、１００
℃で６０分間程度抽出し、固液分離し、得られた分離液
が２分の１ｆｆｉになるまで濃縮し、濃縮液をスプレー
ドライして小続命湯乾燥エキス粉末を得た。Specific example 3: According to the classic Chinese medicine (Bikyu Senkin Yokata), 3 g of apricot kernels, 2 g of wind protection, 2 g of Chinese medicine, 2 g of boi, 29 ephedra, 29 g of huang, 2 g of side horn, 2 g of huang, 2 g of cinnamon, and licorice. 19, add 30 times the volume of purified water to 19 carrots, 19 crude drugs, 0.39 ounces of fuji, and make 100
Extraction was carried out for about 60 minutes at °C, followed by solid-liquid separation, and the resulting separated liquid was concentrated to 1/2 ffi, and the concentrated liquid was spray-dried to obtain a powder of Kozumeito dry extract.
製剤化にあたっては、各々の乾燥エキス粉末に、通常の
製剤に用いる適当な賦形剤、補助剤等を加えて製剤製造
の常法に従って散剤、顆粒剤、錠剤、カプセル剤などの
製剤にすることができる。When formulating, add appropriate excipients, adjuvants, etc. used in ordinary formulations to each dry extract powder, and make formulations such as powders, granules, tablets, capsules, etc. according to the usual method of manufacturing formulations. I can do it.
［発明の効果］
本発明薬剤が降圧作用を有することを実験例を挙げて説
明する。[Effects of the Invention] The fact that the drug of the present invention has a hypotensive effect will be explained with reference to experimental examples.
実験例
組−１
ウィスター系ラット（静岡実験動物センター５ＰＦ）を
６〜７週令で購入し、恒温恒湿（２５°Ｃ１５０％）の
動物室で１週間予備飼育の後、８週令（体重２００９程
度）から実験に用いた。飼料（日本タレア： ＣＥ−２
）および自動給水による水道水は自由に摂取させた。飲
料を１％食塩水とするときは給水瓶を用いて行い、水道
水を断った。Experimental example set-1 Wistar rats (Shizuoka Experimental Animal Center 5PF) were purchased at 6 to 7 weeks of age and preliminarily kept in an animal room at constant temperature and humidity (25°C, 150%) for one week. It was used in experiments from around 2009). Feed (Nippon Talea: CE-2
) and tap water from an automatic water supply were available ad libitum. When drinking 1% saline, use a water bottle and refrain from drinking tap water.
メヂラボン５０肩９を蒸留水５０７に溶解し、２００ｕ
９１０．２ｄの溶液を作成し、この溶液２００通を皮下
投与した。Dissolve Medjirabone 50 Shoulder 9 in distilled water 507, 200u
A solution of 910.2d was prepared and 200 doses of this solution were administered subcutaneously.
５０℃の温熱箱（２８ｃＭＸ ４３ｃＭｘ ２４ｃｘ）
にラットを入れて、２０分間温熱負荷を与えた後、プレ
チスモ式血圧記録計（植田製作所： ＵＳＭ−１０５）
により、非観血的に尾動脈血圧（最高血圧）を測定した
。１匹に対し４回以上の測定から平均値を求め、測定値
とした。この操作は毎日１回行い、血圧値が安定してか
らメチラボン投与と１％食塩水の摂取を開始した。50℃ heating box (28cMX 43cMx 24cx)
After placing the rat in the room and applying a thermal load for 20 minutes, the rat was placed in a plethysmo blood pressure recorder (Ueda Seisakusho: USM-105).
Tail artery blood pressure (systolic blood pressure) was measured non-invasively. The average value was determined from 4 or more measurements for each animal and was used as the measured value. This operation was performed once a day, and after the blood pressure value stabilized, administration of metyrabone and intake of 1% saline were started.
ラットは温熱負荷処置のみによっては高血圧状態を維持
しないが、メチラボン投与と食塩水摂取により、２０日
以上を要して高血圧状態となった。Rats did not maintain a hypertensive state only by thermal stress treatment, but became hypertensive over a period of 20 days or more by administering metyrabone and ingesting saline.
薬剤の調整および投与方法
具体例１〜３で得た乾燥エキス粉末を用時溶解して用い
た。この様にして得られた薬剤の１日の必要用ｍを１日
１の飲料水に加え、８日間Ｍ Ｉ（Ｈに投与した。１日
の必要量は乾燥エキス粉末として、補陽還五湯は２ 、
６２９７に９ ／ｄａｙ、続命湯は０ 、１９／に９
／ｄａｙ、小続命湯は０ 、４１９７に９ ／ｄａｙと
した。乾燥エキス粉末を加えない以外は上記と同様に操
作したしのをコントロールとした。Preparation and administration method of drugs The dried extract powders obtained in Examples 1 to 3 were dissolved before use. The daily required amount of the drug thus obtained was added to drinking water once a day and administered to MI (H) for 8 days.The daily required amount was given as a dry extract powder. 2 hot water,
9/day on 6297, 0 for Shokumeito, 9 on 19/
/day, and Kozutsumeito was 0, and 9 /day in 4197. A control sample was prepared using the same procedure as above except that no dried extract powder was added.
血圧計および測定方法
血圧計はプレチスモ式血圧記録計を用いて、非観血的に
尾動脈血圧を測定した。Sphygmomanometer and measurement method Tail artery blood pressure was measured non-invasively using a plethysmo blood pressure recorder.
１匹に対し４回以上の測定から平均値を求め、測定値と
した。The average value was determined from 4 or more measurements for each animal and was used as the measured value.
その結果を第１表および第２表に示す。The results are shown in Tables 1 and 2.
第１表
第２表
さらに補陽還五渇、続命湯、小続命湯各々の急性ＩｔＬ
性試験についてｄｄＹ系マウスを用いて行ったところ・
、いずれら１５ｇ／＆ｇ（投与限界）の経口投与でも死
亡例はなかった。Table 1 Table 2 In addition, acute ItL of Hoyokangoto, Zokumeito, and Kozokumeito
A sex test was conducted using ddY mice.
There were no deaths even after oral administration of 15 g/&g (dose limit).
以上の結果からコントロールに対して有色に降圧効果が
認められ、さらに急性毒性試験により極めて毒性が低い
ことから、降圧剤としての有用性が確認された。From the above results, a distinct antihypertensive effect was observed compared to the control, and the acute toxicity test showed extremely low toxicity, confirming its usefulness as an antihypertensive agent.
本発明における実験データおよび急性毒性試験の結果か
ら考えて、本発明の降圧剤の有効投与ｍは、患者の年令
、体重、疾患の程度によっても異なるが、補陽還五堝、
続命湯および小続命湯は、各処方通常成人量で乾燥エキ
ス粉末として■日量１〜１０ｇを症状に合わせて、１日
３回に分けての服用量が適当と認められる。Considering the experimental data and acute toxicity test results of the present invention, the effective administration m of the antihypertensive agent of the present invention varies depending on the patient's age, weight, and degree of disease;
It is recognized that it is appropriate for each formulation of Zokumeito and Kozumeito to be administered at a daily dose of 1 to 10 g as dry extract powder in three doses per day, depending on the symptoms.
次に本発明の実施例を挙げ、より具体的に説明するが、
本発明はこれにより何ら制限されるものではない。Next, examples of the present invention will be given to explain more specifically,
The present invention is not limited to this in any way.
実施例１
具体例！で得た乾燥エキス粉末２００ｇを乳糖８９ｇお
よびステアリン酸マグネシウムと混合し、この混合物を
単発弐打鍵機にて、直径２０．、、重量２．３９のスラ
ッグ綻を作り、これをオシレーターにて粉砕し、整粒し
、篩別して２０〜５０メツシユの粒子の良好な顆粒剤を
得た。この顆粒剤は、症状に合わせて各々１回量０゜５
〜４．５９Ｃ乾燥工キス粉末重量として０．３４〜３．
１０９に相当）を１日３回服用する。Example 1 Specific example! 200 g of the dry extract powder obtained in step 1 was mixed with 89 g of lactose and magnesium stearate, and the mixture was mixed with a single-stroke double-key machine into a diameter of 20 mm. A slug with a weight of 2.39 mm was prepared, which was pulverized with an oscillator, sized, and sieved to obtain good granules with particles of 20 to 50 mesh. This granule is available in a single dose of 0.5 depending on the symptoms.
~4.59C drying kiss powder weight 0.34~3.
109) three times a day.
実施例２
具体例２で得た乾燥エキス粉末２００ｇを微結晶セルロ
ース２０９およびステアリン酸マグネシウムと混合し、
この混合物を単発打錠機にて打錠して、直径７ Ｒ１１
、重ｆｆｉ ２２５１ｇの錠剤を製造した。Example 2 200 g of the dry extract powder obtained in Example 2 was mixed with microcrystalline cellulose 209 and magnesium stearate,
This mixture was compressed into tablets using a single-shot tablet machine to form tablets with a diameter of 7 R11.
, heavy ffi 2251 g tablets were produced.
本錠剤中には具体例２で得た乾燥エキス粉末を２００肩
９含有する。本錠剤は症状に合わせて各々１目量２〜１
６錠を１日３回服用する。This tablet contains 200 kg of the dry extract powder obtained in Example 2. This tablet is available in 1 dose of 2-1 depending on the symptoms.
Take 6 tablets 3 times a day.
実施例３
具体例３で得た乾燥エキス粉末５００々２を便カプセル
に充填した。本カプセルは症状に合わせて各々２〜２０
カプセルを１日３回に分けて服用する。Example 3 500 pieces of the dried extract powder obtained in Example 3 were filled into fecal capsules. This capsule contains 2 to 20 capsules each depending on the symptoms.
Take the capsule in three divided doses a day.
Claims (1)
ともひとつの漢方処方を有効成分とする降圧剤。An antihypertensive agent containing at least one Chinese herbal formula selected from Hoyokangoto, Shoseimeito, and Shosetsumeito as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1075196A JPH02255621A (en) | 1989-03-29 | 1989-03-29 | Hypotensor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1075196A JPH02255621A (en) | 1989-03-29 | 1989-03-29 | Hypotensor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02255621A true JPH02255621A (en) | 1990-10-16 |
Family
ID=13569199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1075196A Pending JPH02255621A (en) | 1989-03-29 | 1989-03-29 | Hypotensor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02255621A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188442A2 (en) * | 2000-09-13 | 2002-03-20 | Wei Xiao | Cinnamomi and poria composition, method to prepare the same and uses thereof |
| US8067040B2 (en) | 2006-10-18 | 2011-11-29 | Jiangsu Kanion Pharmaceuticals, Co. Ltd. | Cinnamomi and poria composition and uses thereof |
| CN102697883A (en) * | 2012-06-04 | 2012-10-03 | 蒋月芳 | Plaster for treating osteoarthritis |
| CN103800478A (en) * | 2012-11-14 | 2014-05-21 | 沈锋艳 | Preparation method of ephedra-almond cough-relieving sugared pill |
-
1989
- 1989-03-29 JP JP1075196A patent/JPH02255621A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188442A2 (en) * | 2000-09-13 | 2002-03-20 | Wei Xiao | Cinnamomi and poria composition, method to prepare the same and uses thereof |
| EP1188442A3 (en) * | 2000-09-13 | 2002-11-06 | Wei Xiao | Cinnamomi and poria composition, method to prepare the same and uses thereof |
| US7052700B2 (en) | 2000-09-13 | 2006-05-30 | Jiangsu Kanion Pharmaceutical Co., Ltd. | Cinnamomi and poria composition, method to prepare same and uses thereof |
| US7691387B2 (en) | 2000-09-13 | 2010-04-06 | Jiangsu Kanion Pharmaceutical Co., Ltd | Cinnamomi and poria composition, method to prepare same and uses thereof |
| US8119141B2 (en) | 2000-09-13 | 2012-02-21 | Jiangsu Kanion Pharmaceutical Co. Ltd. | Cinnamomi and poria composition, method to prepare same and uses thereof |
| US8067040B2 (en) | 2006-10-18 | 2011-11-29 | Jiangsu Kanion Pharmaceuticals, Co. Ltd. | Cinnamomi and poria composition and uses thereof |
| CN102697883A (en) * | 2012-06-04 | 2012-10-03 | 蒋月芳 | Plaster for treating osteoarthritis |
| CN103800478A (en) * | 2012-11-14 | 2014-05-21 | 沈锋艳 | Preparation method of ephedra-almond cough-relieving sugared pill |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5936621A (en) | Improving agent for cancerous symptom | |
| JPS5936619A (en) | Carcinostatic adjuvant | |
| WO2011113190A1 (en) | Pharmaceutical composition for treating aids and preparation method thereof | |
| WO2024061140A1 (en) | Traditional chinese medicine composition for treating immune vasculitis and formulation and use thereof | |
| JPH04243832A (en) | Treating agent for autoimmune disease | |
| JPH02255622A (en) | Carcinostatic assistant | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| RU2000120474A (en) | PHARMACEUTICAL COMPOSITION POSSESSING ANTITUM ACTIVITY AND METHOD FOR PRODUCING IT | |
| JPH02255621A (en) | Hypotensor | |
| JPS6025933A (en) | Agent for mitigating symptoms of cancer | |
| JPS6277329A (en) | Aldose reductase inhibitor | |
| JPH01246224A (en) | Remedy for dementia | |
| JPH02152926A (en) | Brain edema depressant | |
| JPS61115029A (en) | Carcinostatic agent | |
| CN1318057C (en) | Method for preparing Chinese medicine formulation for treating gynaecological disease | |
| CN108578541A (en) | A kind of Chinese medical extract that treating rheumatism and cardiovascular and cerebrovascular disease, preparation method and applications | |
| CN104069312B (en) | Treat Chinese medicine composition of apoplexy and preparation method thereof, pharmaceutical preparation and application | |
| JPS61194031A (en) | Agent for promoting carcinostatic activity | |
| CN113521131B (en) | Traditional Chinese medicine composition for ischemic cardiomyopathy and application thereof | |
| CN110604761B (en) | Mulberry flower tablet, preparation process thereof and application thereof in treating cardiovascular and cerebrovascular diseases | |
| CN106491967B (en) | A kind of Chinese medicine composition for being used to treat hypertension | |
| CN104147202B (en) | Benefiting qi and nourishing blood, toxin expelling Fructus Alpiniae Oxyphyllae, Yin Yang balancing, the microcirculatory compositions of improvement and preparation thereof | |
| JPS63239229A (en) | Immunoactivating agent | |
| JPH07309769A (en) | Moistureproof herb granule preparation | |
| JPH01153646A (en) | Antiretrovirus agent |